Evenity (Romosozumab): EMA vs FDA Regulatory Approach

Romosozumab, sold as Evenity and co-developed by Amgen and UCB, is a monoclonal antibody that inhibits sclerostin, a protein that otherwise suppresses bone formation. It is FDA-approved and EMA-authorized for osteoporosis in postmenopausal women at high fracture risk, and both agencies later extended approval to men at high fracture risk. Both regulators reviewed the same core trial program and reached different label decisions on cardiovascular risk: the FDA approved the drug with a boxed warning that leaves the prescribing decision to the clinician, while the EMA initially rejected it and then approved it with an absolute contraindication in patients with a history of myocardial infarction or stroke. That divergence, not the drug's fracture-prevention efficacy, is the substance of this comparison.

What is actually established here

Romosozumab's two pivotal trials point in different directions on cardiovascular safety. ARCH compared romosozumab to an active comparator, alendronate, in women with a prior fragility fracture, and reported more serious cardiovascular events in the romosozumab arm during the treatment period. FRAME compared romosozumab to placebo in a broader osteoporosis population and did not report a comparable imbalance. A meta-analysis combining trial-level data with Mendelian randomization evidence on sclerostin pathway variants examined this exact question, asking whether genetically lower sclerostin activity is associated with cardiovascular risk independent of any single trial's comparator choice (Bovijn et al., evaluating cardiovascular safety of sclerostin inhibition). That kind of triangulation, combining randomized trial data with genetic evidence, is the right way to ask whether ARCH's signal reflects a drug effect, a comparator artifact, or noise. The honest answer, based on the evidence available, is that the question has not been fully closed either way, which is precisely why the FDA and EMA reached different label conclusions from the same dossier rather than one of them being simply wrong.

Because the source citations available for this draft could not be independently verified against the underlying trial publications, this article does not reproduce exact event-rate percentages, vote counts, or statistical results from ARCH, FRAME, or the post-marketing registries. Readers who need those figures for clinical decision-making should pull them directly from the FDA label, the EMA EPAR, or the primary trial publications rather than from secondary summaries.

FDA: approval with a boxed warning

Romosozumab received FDA approval on April 9, 2019, based on a determination that its fracture-prevention benefits in high-risk postmenopausal women outweighed identified safety concerns. A boxed warning appears in the prescribing information for romosozumab, flagging elevated risks of myocardial infarction, stroke, and cardiovascular death (FDA prescribing information). While the label recommends against use within one year of myocardial infarction or stroke, it does not prohibit prescribing in these patients entirely. Clinicians may administer romosozumab to patients with prior cardiovascular events if they document that the expected fracture-prevention benefit justifies the cardiovascular risk. An FDA advisory committee examined ARCH cardiovascular findings prior to approval and evaluated them alongside romosozumab's fracture-prevention efficacy; however, the specifics of that deliberation are not detailed here due to verification limitations. Vote tallies from the advisory committee meeting are omitted pending verification; readers requiring such details should consult the FDA's official meeting transcript.

EMA: rejection, then a narrower approval

The EMA's Committee for Medicinal Products for Human Use took a harder initial position. It issued a negative opinion in 2019, concluding that the cardiovascular signal outweighed the benefit for the originally proposed indication. Amgen and UCB requested a re-examination, and the CHMP reversed course later that year, recommending approval with a narrower indication restricted to postmenopausal women at high fracture risk with no history of myocardial infarction or stroke. The European Commission granted marketing authorization in December 2019. The EMA's assessment report and current label are the authoritative source for the exact indication wording and contraindications (EMA EPAR for Evenity).

Why the two labels differ in kind, not just wording

The FDA's boxed warning and the EMA's contraindication are not just different phrasings of the same restriction. A boxed warning is a communication mechanism: it forces the prescriber to see the risk and weigh it, but leaves the final decision to clinical judgment. A contraindication is a prohibition: an EU-labeled prescriber cannot legally give romosozumab to a patient with a qualifying MI or stroke history, regardless of how high that patient's fracture risk is otherwise. This means a postmenopausal woman with severe osteoporosis and a stroke in her history could be eligible for the drug under the US label's risk-benefit framework but categorically excluded under the EU label. Both agencies were reacting to the same ARCH signal; they differed on how much of the residual uncertainty to hand to the individual clinician versus resolve by rule.

Both agencies agree on other points: treatment is limited to 12 monthly doses, repeat courses are not approved by either label, and patients are expected to transition to an anti-resorptive agent such as denosumab or a bisphosphonate afterward to preserve bone density gains. Both regulators also required continued post-marketing cardiovascular surveillance, though the specific study designs and reporting schedules should be confirmed against each agency's own risk management documentation rather than assumed from secondary sources. The FDA's general-purpose active surveillance system, Sentinel, is one of the tools available to it for this kind of post-market signal detection (FDA Sentinel Initiative).

Decision framework: which label logic fits which patient

This table compares the FDA and EMA approaches on the criteria that actually change a treatment decision, rather than restating the labels side by side.

This is a comparison of regulatory posture, not a substitute for the current label text. Prescribers should confirm the operative wording against the FDA label and EMA EPAR before making a treatment decision, since labels can be updated.

What is established, what is plausible, and what is not established

Established: The FDA approved romosozumab in April 2019 with a boxed cardiovascular warning; the EMA rejected it, then approved a narrower indication in December 2019 with an absolute MI/stroke contraindication; both labels cap treatment at 12 monthly doses with no approved repeat course; both agencies required continued post-market cardiovascular monitoring.

Plausible but unproven: That the cardiovascular imbalance observed in the active-comparator trial reflects a true drug effect of romosozumab rather than an artifact of the comparator's own cardiovascular profile. Human-genetics-based analyses of sclerostin pathway variants have been used to probe this question, but a definitive resolution is not established in the sources reviewed for this article.

Not established: Long-term cardiovascular safety beyond the trial and early post-marketing follow-up windows, the safety of a second treatment course, and whether either agency's current cardiovascular restriction will still be justified once the mandated post-marketing studies mature. Readers should not treat the current label restrictions as a final scientific verdict; they are the two agencies' best risk-management judgment given the evidence available at the time of approval.

Practical questions this raises for prescribers and patients

A patient with a distant cardiovascular event, well outside any 12-month exclusion window, still needs an individualized conversation about residual risk; the label distinctions above do not automatically resolve that case. A clinician considering romosozumab for a patient with cardiovascular risk factors that fall short of a qualifying event (hypertension, dyslipidemia, diabetes) should note that neither label explicitly addresses this population, and that baseline cardiovascular assessment before starting the drug reflects clinical caution rather than a labeled requirement. Anyone experiencing chest pain, one-sided weakness, sudden severe headache, or other symptoms suggestive of MI or stroke while on romosozumab needs urgent medical evaluation, not a wait-and-see approach; this is standard cardiovascular emergency guidance and does not depend on which country's label applies.